Following a near-breakeven during FY25, diagnostics and wellness testing platform Healthians turned profitable for the first time in the fiscal year ending March 2026, while continuing to scale its business. Healthians’ revenue from operations grew 35.7% year-on-year to Rs 357 crore in FY26 fromRs 263 crorein FY25, according to its consolidated financial statements reviewed byEntrackr. The Gurugram-based company offers at-home diagnostic services across more than 250 cities and claims to have conducted over 10 crore tests to date. Diagnostics remained its biggest revenue driver, contributing 99% of the operating revenue, or Rs 353 crore, during the fiscal year. The remaining income came from supplementary and ancillary services. Healthians also earned Rs 5 crore in interest income, taking its total revenue to Rs 362 crore in FY26 from Rs 270 crore in FY25. On the cost front, employee benefits remained the company’s largest expense, accounting for 36.8% of its total expenditure. The expense rose 28% year-on-year to Rs 134 crore in FY26. The cost of materials stood at Rs 109 crore, while marketing expenses declined to Rs 44 crore. Rent, legal, information technology and other overheads pushed Healthians’ total expenditure up 32.4% to Rs 364 crore in FY26 from Rs 275 crore in FY25. With revenue growing faster than expenses, Healthians turned profitable and posted a net profit of Rs 5.4 crore in FY26, compared with a loss of Rs 4.77 crore in FY25. The company, however, continued to carry accumulated losses of Rs 976 crore. On a unit economics basis, Healthians spent Rs 1.02 to earn every rupee of operating revenue in FY26. Its EBITDA margin improved to 2.20%, while ROCE stood at -4.86%. At the end of FY26, the company had current assets worth Rs 112.5 crore. Healthians has raised around $75 million in funding to date, with WestBridge, BEENEXT, DG Ventures and YouWeCan among its key investors. The Bengaluru-based company competes with Orange Health, Redcliffe Labs, Dr Lal PathLabs and other diagnostic players. The financial turnaround comes amid a leadership transition at Healthians. FounderDeepak Sahnistepped away from all formal executive responsibilities in January 2026 after spending a decade building the company. While getting close to operating profitability should be welcome, as the numbers show, Healthians has a long way to go yet. Growth from here will hardly be linear, with the high competition in the market and pressure on margins from that. What the competition has achieved is definitely a push for more diagnostics by both institutions and individuals themselves, a trend that would be welcome but for the rising pushback against what many consider ‘unnecessary’ tests. Expanding this market further would need testing solutions that provide a significant indicator of future risks and actions that can be taken in the present. Be it the use of AI or newer approaches to diagnosis beyond the staple blood tests. As a very technology led firm, Heal
